Double-blind comparison of fluoxetine and desipramine in the treatment of depressed women with advanced HIV disease: a pilot study.
A double-blind, placebo-controlled study was conducted to assess the relative efficacy and tolerability of fluoxetine and desipramine in depressed, human immunodeficiency virus (HIV)-positive women. Although difficulty in the recruitment and retention of participants led to insufficient power to detect differences between treatment groups, results indicated that participants experienced improvement in their depression. However, for most women, significant depressive symptoms remained after 6 weeks of treatment. In addition, although most participants reported at least one adverse event after treatment began, most of the side effects, regardless of treatment condition, were mild to moderate in severity. Important barriers to study participation and completion are discussed, as well as suggestions for increasing the involvement of depressed, HIV-positive women in future treatment studies.
Schwartz
J A
JA
Emory University School of Medicine, Department of Psychiatry and Behavioral Sciences, Grady Health System Infectious Disease Program, Atlanta, Georgia, USA.
McDaniel
J S
JS
D000328:Adult; D003866:Depressive Disorder / Q000150:complications* / Q000188:drug therapy*; D003891:Desipramine / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D005473:Fluoxetine / Q000627:therapeutic use*; D015658:HIV Infections / Q000150:complications*; D006801:Humans; D010865:Pilot Projects; D011569:Psychiatric Status Rating Scales
D005473:Fluoxetine; D003891:Desipramine